EUVIMEDEUVIMED entdecken
Crossref

Design, Characterization and In Vitro Evaluation of Carbamazepine Loaded Mucoadhesive Nanogel for Nose-to-Brain Drug Delivery to Improve Epilepsy Management

Amudhavalli Victor, Varunyaa Sri M, Arin Bhattacarya, Prachet Pinnamaneni, Taufik Mulla, Anitha A, Hasnat Fatima, Vaibhav Gawade

International Journal of Drug Delivery Technology · 14.04.2026 · 16 (9s)

DOI: 10.25258/ijddt.16.9s.104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 14.04.2026. Verfasst von Amudhavalli Victor und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Refractory epilepsy remains a significant neurological challenge, affecting approximately one-third of patients who fail to achieve adequate seizure control with conventional antiepileptic drugs. Carbamazepine, a first-line therapy for focal and generalized tonic–clonic seizures, suffers from poor solubility, variable bioavailability, and extensive hepatic metabolism, limiting its clinical efficacy. This study aimed to develop and evaluate a carbamazepine-loaded nanogel for intranasal delivery to enhance brain targeting and overcome the limitations of oral therapy. Nanogels were prepared via ionic gelation and incorporated into a Carbopol–HPMC gel base, followed by comprehensive in vitro characterization. The optimized formulation exhibited a particle size of 145.6 ± 4.2 nm, a zeta potential of –32.5 ± 1.5 mV, and high entrapment efficiency (89.6 ± 2.1%). Drug release studies demonstrated a biphasic profile with sustained release over eight hours, best fitting the Higuchi model (R² = 0.991), indicating diffusion-controlled kinetics. Ex vivo permeation studies confirmed a 2.1-fold enhancement in nasal mucosal penetration compared to a plain gel. FTIR and DSC analyses revealed no drug–excipient incompatibility, and stability testing under ICH conditions confirmed formulation integrity. These findings suggest that nanogel-based intranasal delivery is a promising strategy for improved brain targeting of carbamazepine, potentially offering enhanced therapeutic outcomes for refractory epilepsy patients.

Zitieren

APA

Victor, A., M, V. S., Bhattacarya, A., Pinnamaneni, P., Mulla, T., A, A., Fatima, H., & Gawade, V. (2026). Design, Characterization and In Vitro Evaluation of Carbamazepine Loaded Mucoadhesive Nanogel for Nose-to-Brain Drug Delivery to Improve Epilepsy Management. International Journal of Drug Delivery Technology, 16(9s). https://doi.org/10.25258/ijddt.16.9s.104

Vancouver

Victor A, M VS, Bhattacarya A, Pinnamaneni P, Mulla T, A A, et al. Design, Characterization and In Vitro Evaluation of Carbamazepine Loaded Mucoadhesive Nanogel for Nose-to-Brain Drug Delivery to Improve Epilepsy Management. International Journal of Drug Delivery Technology. 2026;16(9s). doi:10.25258/ijddt.16.9s.104

BibTeX
@article{Victor2026,
  author = {Victor, Amudhavalli and M, Varunyaa Sri and Bhattacarya, Arin and Pinnamaneni, Prachet and Mulla, Taufik and A, Anitha and Fatima, Hasnat and Gawade, Vaibhav},
  title = {Design, Characterization and In Vitro Evaluation of Carbamazepine Loaded Mucoadhesive Nanogel for Nose-to-Brain Drug Delivery to Improve Epilepsy Management},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {9s},
  doi = {10.25258/ijddt.16.9s.104}
}
Kostenlos starten →